Phase II trial of adjuvant TC (docetaxel/cyclophosphamide) plus trastuzumab in HER2 [human epidermal growth factor receptor 2]-positive early stage breast cancer patients

Trial Profile

Phase II trial of adjuvant TC (docetaxel/cyclophosphamide) plus trastuzumab in HER2 [human epidermal growth factor receptor 2]-positive early stage breast cancer patients

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Nov 2016

At a glance

  • Drugs Docetaxel (Primary) ; Cyclophosphamide; Trastuzumab
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 05 Nov 2016 Last checked against ClinicalTrials.gov record.
    • 20 May 2014 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top